Defiance Daily Target 2X Long NVO ETF(NVOX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVOX Defiance Daily Target 2X Long NVO ETF

Post-Mkt 09-25 17:11:40 EDT

9.87

+0.08

+0.82%

盘后9.87

+0.000.00%

17:08 EDT

High9.90	Low9.69	Vol281.63K
Open9.90	D1 Closing9.79	Amplitude2.15%
Mkt Cap35.22M	Tradable Cap35.22M	Total Shares3.57M
T/O2.76M	T/O Rate7.89%	Tradable Shares3.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"Defiance Daily Target 2X Long NVO ETF","latestPrice":9.87,"timestamp":1790366400000,"preClose":9.79,"halted":0,"volume":281634,"hourTrading":{"tag":"盘后","latestPrice":9.87,"preClose":9.87,"latestTime":"17:08 EDT","volume":530,"amount":5218.98261,"timestamp":1790370518369,"change":0,"changeRate":0,"amplitude":0.006069},"delay":0,"changeRate":0.008171603677221662,"floatShares":3568100,"shares":3568100,"eps":0,"marketStatus":"Post-Mkt","change":0.08,"latestTime":"09-25 17:11:40 EDT","open":9.9,"high":9.9,"low":9.69,"amount":2758829.492298,"amplitude":0.02145,"askPrice":9.87,"askSize":2000,"bidPrice":9.83,"bidSize":3,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790380800000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":9.79,"sharesOutstanding":4098101,"nav":9.58,"aum":34182407.58,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":9.91,"preClose":9.79,"latestTime":"09:27 EDT","volume":7735,"amount":75859.009135,"timestamp":1790342829924,"change":0.12,"changeRate":0.012257,"amplitude":0.019377},"postHourTrading":{"tag":"盘后","latestPrice":9.87,"preClose":9.87,"latestTime":"17:08 EDT","volume":530,"amount":5218.98261,"timestamp":1790370518369,"change":0,"changeRate":0,"amplitude":0.006069},"volumeRatio":0.253784,"impliedVol":0.6291,"impliedVolPercentile":0.108},"requestUrl":"/m/hq/s/NVOX/tweets","defaultTab":"tweets","newsList":[{"id":"1129613388","title":"Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance","url":"https://stock-news.laohu8.com/highlight/detail?id=1129613388","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129613388?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:51","pubTimestamp":1790337115,"startTime":"0","endTime":"0","summary":"Novo Nordisk this week unveiled an ambitious strategy aimed at reigniting growth beyond its flagship injections Wegovy and Ozempic, but the road back to winning investors and reclaiming share in the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","SGXZ31699556.SGD","LU2211815571.USD","SG9999014906.USD","LU0225283273.USD","BK4516","LU2361045086.USD","LU0823434583.USD","MEDX","TRUH","GB00BDT5M118.USD","LU0096364046.USD","LU2357305700.SGD","LU2471134952.CNY","LU0432979614.USD","LU1868836914.USD","LU0354030511.USD","LU2213496289.HKD","NVO","LU1093756168.USD","LU1868837136.USD","LU2168564495.EUR","LU2028103732.USD","JDOC","SG9999014880.SGD","LU0466842654.USD","LU2750360997.AUD","BK4534","IE00B4JS1V06.HKD","IE00BN29S564.USD","LU0238689110.USD","LU2271345857.HKD","SG9999014898.SGD","IE00B4R5TH58.HKD","LU0943347566.SGD","LU2746668461.USD","LLYX","LU0708995401.HKD","LU2236285917.USD","IE0005OL40V9.USD","NVOC","SG9999014914.USD","LU1989771016.USD","LU0203202063.USD","MEDI","IE0002141913.USD","IE00BWXC8680.SGD","LU1280957306.USD","LU0210536198.USD","HRTS","LU1623119135.USD","LU2750360641.GBP","BK4007","PPH","LU1127390331.HKD","LU2023251221.USD","BK4599","IE00BKDWB100.SGD","IE00B1BXHZ80.USD","IE00B7KXQ091.USD","LU0256863902.USD","LU0882574139.USD","LU2456880835.USD","LU2491049909.HKD","LU2491050154.USD","SGXZ51526630.SGD","LU0158827781.USD","LU0320765992.SGD","LU0256863811.USD","LU2471134796.USD","SG9999017495.SGD","OZEM","SG9999018857.SGD","LU0964807845.USD","LU2324357040.USD","LU1983299246.USD","LU0058720904.USD","LLII","LU0114720955.EUR","LU1917777945.USD","LU2089284900.SGD","IXJ","AGNG","FHLC","LU2462157665.USD","LU0353189763.USD","IE00B2B36J28.USD","LU2602419157.SGD","LU2417539215.USD","LU2108987350.USD","LU2461242641.AUD","NVOH","SGXZ81514606.USD","LU0097036916.USD","LU0689472784.USD","LU0820561909.HKD","LU0345770993.USD","LU2112291526.USD","IE0009355771.USD","CANC","LU1267930730.SGD","LU1548497426.USD","IE00BFTCPJ56.SGD","ILDR","LU0154236417.USD","LU0174119429.USD","LU0417517546.SGD","BK4588","LU1979441026.SGD","LU2360106947.USD","LLY","BK4581","LU0061475181.USD","LU2089283258.USD","LU0289739699.SGD","GDOC","LU0094547139.USD","LU2063271972.USD","LU1691799644.USD","LU2237443465.HKD","LU2237443622.USD","LU2111349929.HKD","LU1712237335.SGD","XLV","LU0353189680.USD","IE0004445015.USD","CURE","LU0203201768.USD","SG9999001176.USD","LU0820561818.USD","LU0823434740.USD","MHIP","LU2462591350.SGD","LU1868837300.USD","LU2361044865.SGD","IE00BZ1G4Q59.USD","LU2237443382.USD","LU1868836757.USD","LU1061106388.HKD","LU1145028129.USD","LU1868836591.USD","LU2264538146.SGD","NVOX","SGXZ99366536.SGD","LU0323591593.USD","LU1720051108.HKD","LU2023250330.USD","PJP","IE00BJLML261.HKD","IE00BJT1NW94.SGD","IE00BFSS7M15.SGD","LU1629891620.HKD","LU1814569148.SGD","LU0385154629.USD","LU2237443978.SGD","LU1323610961.USD","LU0198837287.USD","LU0122379950.USD","LU0006306889.USD","LU0345770308.USD","SG9999018865.SGD","SGXZ57979304.SGD","SG9999001176.SGD","LU1291159041.SGD","LU2471134879.HKD","LU2168564149.EUR","ELIS","LU2237443549.SGD","LU1551013425.SGD","BK4532","RXL","BK4585","LU2265009873.SGD","LU2896262040.SGD","SG9999013999.USD","SG9999015945.SGD","LU0354030438.USD","LU0787776722.HKD","LU1035775433.USD","LU2468319806.SGD","VHT","LU2168563687.JPY","LU1366192091.USD","LU1093756325.SGD","LU2237438978.USD","LU2168564222.USD","LU1232071149.USD","LU0234572021.USD","LU0456855351.SGD","LU1974910355.USD","LU0683600562.USD","LU1069344957.HKD","LU1988902786.USD","LU1551013342.USD","THNR","IE00BJJMRY28.SGD","LU0786609619.USD","LU2106854487.HKD","LU2361044949.HKD","LU1057294990.SGD","LU2237443895.HKD","IE00BFSS8Q28.SGD","IE0004445239.USD","LU1064131342.USD","BK4533","LU0823416689.USD","LU2168564065.EUR","LU0471298694.HKD","LU0640476718.USD","LU2087625088.SGD","LU1720051017.SGD","LU2756315664.SGD","LU0133085943.USD","LU2491050071.SGD","LU0266013472.USD","LU0106261372.USD","LU2552382132.HKD","WDNA","LU1804176565.USD","LU0109391861.USD","LU2746668974.SGD","LU0079474960.USD","LU0672654240.SGD","LU0889565916.HKD","LU0882574055.USD","LU2552382215.SGD","LU2756315318.SGD","LU0820562030.AUD","IE0001KFT4U8.USD","LU2552382058.USD","SG9999015986.USD","IE00B775H168.HKD","IE00BK4W5L77.USD","TMED","IE00BKVL7J92.USD","LU0471298777.SGD","LU0109394709.USD","SG9999015978.USD","IE00BKPKM429.USD","LU0320765059.SGD","FTXH","IE00BJJMRX11.SGD","LU2089984988.USD","ELIL","IYH","LU1023059063.AUD","LU0158827948.USD","LU2471134523.USD","IE00B1XK9C88.USD","LLYZ","SG9999015952.SGD","LU2023250504.SGD","LU0316494557.USD","IE00BK4W5M84.HKD","IHE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670494824","title":"After Capital-Markets Day Flop, Novo Strikes Licensing Deal That Sends a Swedish Company's Stock Soaring","url":"https://stock-news.laohu8.com/highlight/detail?id=2670494824","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670494824?lang=en_us&edition=fundamental","pubTime":"2026-09-25 17:11","pubTimestamp":1790327460,"startTime":"0","endTime":"0","summary":"Novo Nordisk struck a licensing deal with a Swedish company worth over $1 billion.Just days after a capital-markets day left investors wondering what's next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.The deal announced on Thursday give Novo a global exclusive license to a drug-delivery technology platform from Sweden's Nanexa for certain therapeutic peptide drugs in medical conditions including obesity, type 2 diabetes and other cardiometabolic diseases.Novo is the company behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, but investors are concerned that its next-generation products are lacking.Nanexa is eligible to receive upfront consideration and potential milestone payments totaling up to EUR1.17 billion , including EUR615 million in upfront payment and development and regulatory milestones. In addition, the agreement provides for low single-digit royalties on future product sales.The news sent the Swedish company  , wh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","BK4585","BK4532","OZEM","NRNVF","BK4599","LU1093756168.USD","NVOX","IE00BZ1G4Q59.USD","BK4007","LU1093756325.SGD","NVOC","PPH","LU0154236417.USD","NVO","THNR","NVOH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670445217","title":"Novo Nordisk Licenses Nanexa Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2670445217","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670445217?lang=en_us&edition=fundamental","pubTime":"2026-09-25 15:46","pubTimestamp":1790322401,"startTime":"0","endTime":"0","summary":"Novo Nordisk  agreed to a global exclusive license with Nanexa to use the latter's PharmaShell drug delivery technology in up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions, Nanexa said Thursday.The companies will develop long-acting injectable formulations with target dosing schedules of once monthly or once quarterly, Nanexa saidThe company said it is eligible for up to 1.17 billion euros  in total payments, including 615 million euros in upfront and development and regulatory milestones.The remaining payments are tied to sales milestones, Nanexa said, adding it will also receive low-single-digit royalties on global net sales of products developed under the agreement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BKVL7J92.USD","PPH","THNR","BK4007","BK4585","BK4532","BK4599","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","NVOC","NVOH","BK4588","NVOX","OZEM","LU1093756325.SGD","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2670490065","title":"Cboe data shows mixed options sentiment in Novo Nordisk with shares up 0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670490065","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670490065?lang=en_us&edition=fundamental","pubTime":"2026-09-25 03:55","pubTimestamp":1790279714,"startTime":"0","endTime":"0","summary":"Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares up 36c, or 0.96%, near $38.53. Options volume more than double the daily...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-novo-nordisk-with-shares-up-0-96-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-novo-nordisk-with-shares-up-0-96-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVOH","THNR","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756325.SGD","BK4588","BK4007","NVOC","OZEM","PPH","NVO","LU1093756168.USD","NVOX","BK4532","BK4585","BK4599","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670494748","title":"Novo Nordisk A/S Series B Stock Rises Thursday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2670494748","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670494748?lang=en_us&edition=fundamental","pubTime":"2026-09-25 00:03","pubTimestamp":1790265780,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B rose 0.3% to DKK253.00 Thursday on what proved to be an overall poor trading session for the stock market, with the OMX Nordic 40 Index falling 1.3% to 2,614.61.The stock's rise  snapped a three-day losing streak.The company closed DKK156.95 below its 52-week high of DKK409.95, which the company achieved on January 23, 2026.Trading volume was 7,386,035, compared to the 50-day average trading volume of 4,650,963.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","NVO","LU0154236417.USD","NVOC","BK4599","LU1093756325.SGD","IE00BKVL7J92.USD","OZEM","NVOH","BK4588","LU1093756168.USD","BK4007","PPH","BK4532","THNR","BK4585","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196528349","title":"Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196528349","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196528349?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:38","pubTimestamp":1790260696,"startTime":"0","endTime":"0","summary":"Pharmaceutical stocks jumped. Moderna, Eli Lilly rose over 3%; Novavax, Pfizer rose around 2%; Merck, Novo Nordisk rose over 1%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","REGN","NVOC","MRNY","JNJ","AMGN","ABBV","GSKH","ABT","NVOX","ELIL","LLYX","LLII","AZN","GSK","MRNA","NVO","BIIB","VIR","BNTX","NVS","NVAX","MRK","SNY","BMY","ELIS","VERU","LLY","GILD","MRNX","PFE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191747742","title":"Novo Nordisk's new strategy hinges on something it cannot manufacture: investor confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=1191747742","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191747742?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:51","pubTimestamp":1790239896,"startTime":"0","endTime":"0","summary":"The key takeaway is that Novo Nordisk laid out ambitious goals on Monday, planning to launch at least five potential blockbuster drugs by 2030, yet its share price plunged 8% after the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","PPH","BK4585","BK4532","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVOX","BK4588","OZEM","IE00BKVL7J92.USD","BK4007","NVO","NVOC","THNR","BK4599","LU0154236417.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189553945","title":"Morning Brief | October Hike Odds Near Seventy Percent As Nasdaq Falls Over One Percent; Cybersecurity Bucks The Trend, TSMC To Lift Prices Three To Six Percent Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1189553945","media":"Options & Short Sell","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189553945?lang=en_us&edition=fundamental","pubTime":"2026-09-24 09:42","pubTimestamp":1790214127,"startTime":"0","endTime":"0","summary":"","market":"other","thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/2521.webp","type":0,"news_type":0,"thumbnails":["https://news-video-sg.skytigris.cn/videos/covers/2521.webp"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Morning Brief | October Hike Odds Near Seventy Percent As Nasdaq Falls Over One Percent; Cybersec...","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESmain","GOOX","SKHA","FBL","SPAL","AMDG","NVDL","SPAX","MCD","NOK","NVD","MSFD","SSPC","HYNX","AMZP","METG","NVC","MSFO","SKHY","SPCG","KJD","AMZW","NVDY","YSPC","APLY","AMZN","SKUU","ELOL","TSM","DAMD","NVDD","NVYY","SNK","AVGU","AMZU","MSFC","AMZY","AVGW","GOOL","NVDU","METU","AMZO","WDC","DSPC","GOOG","AAPW","MULL","NVOH","INTC","KBDU","AMAA","SKHN","MSFY","LOFF","MIC","AVGC","BABW","BABX","INT","ANV","SPCH","NVDA","AAPU","AVGO","BABU","GOOY","STSM","NVDO","AMD","SKHZ","SKHL","AMZD","07788","SNDC","AMUU","INYY","FBY","METQ","AAPE","NVDX","SNDK","AAPL","MSFW","GGLL","07388","MU","BBYY","GOOGL","GOOW","SNDU","BABA","SPCQ","MUU","AVGG","BABC","INTW","07709","NQmain","KPDD","NVII","MUG","MSFL","SKHU","TSMZ","AAPD","AZYY","SNDG","NVDB","GGLS","GOU","MUZ","AMDW","FBYY","SPCX","AVGX","NVDW","YMmain","LNOK","AMYY","TSMU","JD","WDCX","AMZG","AAPY","PDDL","MSFT","SKHX","SKHQ","NVOC","AMZZ","SPCM","METD","GOOP","NVO","LINT","METW","AMDC","DIPS","TSMX","MUD","AVL","SNXX","SPCU","META","AVS","TSMY","FBX","AMDD","PDD","LOFD","AAPX","GOGL","MSFX","NVOX","KBAB","SNDQ","NVDS","SK","TWSC","SKDD","IOSX","NVDG","BIDU","TSMG","AAPB","BIDG","BABO","AMDL","NVDQ","MSFU","SPCF","MUYY","WDCC","AMDY"],"isVideo":true,"video":{"duration":391,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/2521/render_2521_1790211760602.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/2521.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/2521/tts/voiceover_0bf09602fa7d054c.mp3","isAI":true},"gpt_icon":0},{"id":"2669436112","title":"Novo Nordisk A/S Stock (NVO) Closed Down by 3.12% on Sep 23: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2669436112","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669436112?lang=en_us&edition=fundamental","pubTime":"2026-09-24 04:15","pubTimestamp":1790194525,"startTime":"0","endTime":"0","summary":"• Novo Nordisk shares dropped following disappointing long-term revenue growth targets.\n• Intensifying competition, patent cliff risks, and market share losses weighed heavily.\n• Technical indicators show sell signals with an RSI of 27.877.","market":"fut","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262183539-market-movers-nvo-20260923","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1093756325.SGD","BK4599","BK4585","LU1093756168.USD","NVOX","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4588","NVO","BK4007","THNR","NVOH","NVOC","LU0154236417.USD","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669791487","title":"Novo Nordisk A/S Series B Stock Falls Wednesday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2669791487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669791487?lang=en_us&edition=fundamental","pubTime":"2026-09-24 00:02","pubTimestamp":1790179320,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B shed 2.5% to DKK252.25 Wednesday on what proved to be an overall negative trading session for the stock market, with the OMX Nordic 40 Index falling 0.8% to 2,648.31.This was the stock's third consecutive day of losses.The company closed DKK157.70 short of its 52-week high of DKK409.95, which the company achieved on January 23, 2026.Trading volume was 5,754,249, compared to the 50-day average trading volume of 4,611,738.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","PPH","BK4585","BK4532","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVOX","BK4588","OZEM","IE00BKVL7J92.USD","BK4007","NVO","NVOC","THNR","BK4599","LU0154236417.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669826694","title":"Novo Nordisk says CagriSema delivers ‘superior’ weight loss in REIMAGINE 5 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669826694","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669826694?lang=en_us&edition=fundamental","pubTime":"2026-09-23 22:40","pubTimestamp":1790174414,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NVO) this week announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema, an investigatio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-says-cagrisema-delivers-superior-weight-loss-in-reimagine-5-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-says-cagrisema-delivers-superior-weight-loss-in-reimagine-5-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","LU1093756325.SGD","BK4585","BK4599","THNR","NVOX","IE00BZ1G4Q59.USD","NVOC","OZEM","NVO","PPH","BK4588","BK4007","LU1093756168.USD","LU0154236417.USD","NVOH","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669884054","title":"The Stock Market is Sleeping on the Next Big AI Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2669884054","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669884054?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:37","pubTimestamp":1790163420,"startTime":"0","endTime":"0","summary":"Fed's Barkin warns that inflation is a 'troublemaker'Inflation is proving to be a \"troublemaker\" for the central bank, according to Richmond Fed President Tom Barkin, who told the CFA Society of Baltimore that inflationary pressures from businesses struggling with higher operating costs are still building in some areas. Read more about what could come next here.&#128241; Meta's Muse is stirring up AI disruption fearsFears are spiraling that Meta Platforms' new Muse AI model could disrupt a variety of industries ahead of the tech giant's Connect conference today and tomorrow. The virtual personal assistant can do a variety of tasks including booking appointments and travel, ordering items on retail sites, choosing insurance, and set up stock trades.&#128137; Lilly and Novo aren't the only weight-loss game in townThe success of Eli Lilly and Novo Nordisk in the weight loss drug realm is attracting newer entrants, including Viking Therapeutics, which just got some positive test resu","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPL","FDTX","AIFD","METU","AAPU","SMETAmain","AAPX","AIPO","JGRO","SMHX","VTHR","RSPC","NVOX","VT","SPTE","WUGI","OGIG","CMAG","MRVU","CHAT","AAPD","QTOC","AIS","GXPC","NVOH","XDAT","SOXY","SAAPLmain","MRVL","XLC","NULC","FAI","VOX","MVLL","ARTY","NVO","XNTK","META","AAPW","GAMR","THNR","FXL","AGIX","VKTX","GTEK","ABFL","APLY","LTL","METV","FCOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669109600","title":"Novo Nordisk Gets Regulatory Nod in Singapore for Wegovy Treatment of Certain Liver Ailments","url":"https://stock-news.laohu8.com/highlight/detail?id=2669109600","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669109600?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:39","pubTimestamp":1790152792,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NVO) has won approval from Singapore authorities for the use of its weight-loss drug, Wegovy, to treat certain liver diseases, the drugmaker said Wednesday.Wegovy, a once-weekly injectab","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVOX","BK4585","NVOH","PPH","NVO","IE00BKVL7J92.USD","THNR","BK4007","LU1093756168.USD","IE00BZ1G4Q59.USD","OZEM","LU1093756325.SGD","BK4599","LU0154236417.USD","BK4588","BK4532","NVOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177534","title":"Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177534","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177534?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:21","pubTimestamp":1790151673,"startTime":"0","endTime":"0","summary":"UPDATE 1-Novo Nordisk open to direct New York listing, CEO Doustdar tells FTSept 23 (Reuters)-Novo NordiskNOVOb.COis open to considering a direct New York Stock Exchange listing, replacing the America","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL6N45F05A:2","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURE","MEDX","LU2324357040.USD","FHLC","FTXH","IE00BJJMRY28.SGD","LU0133085943.USD","IXJ","XLV","TMED","IYH","NVOX","NVO","RXL","MEDI","THNR","VHT","LU0640476718.USD","LU0345770308.USD","LU2168564065.EUR","HRTS","LU1623119135.USD","LU2028103732.USD","PJP","LU0354030511.USD","WDNA","BK4534","NVOC","CANC","LU0114720955.EUR","SGXZ99366536.SGD","AGNG","OZEM","GDOC","LU2471134796.USD","MHIP","IHE","ILDR","JDOC","IE00BFTCPJ56.SGD","IE0009355771.USD","LLYZ","LU0320765992.SGD","LU1023059063.AUD","LU2462157665.USD","NVOH","TRUH","LU1868836591.USD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669106133","title":"Market Chatter: Novo Nordisk Mulls Direct NYSE Listing to Boost US Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2669106133","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669106133?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:05","pubTimestamp":1790150726,"startTime":"0","endTime":"0","summary":"Novo Nordisk  signaled it may consider upgrading its New York listing as it looks to raise its profile in the US market, the Financial Times reported Wednesday, citing chief executive Mike Doustdar.Doustdar said he sees potential advantages in listing shares directly on the New York Stock Exchange rather than relying on American depositary receipts, though the company is not actively pursuing the move, according to the FT.The US accounts for more than half of Novo's revenue and most of its sales of diabetes and obesity treatments, according to the report.Novo Nordisk did not immediately respond to MT Newswires' request for comment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BKVL7J92.USD","NVO","PPH","IE00BZ1G4Q59.USD","NVOC","THNR","BK4585","LU0154236417.USD","BK4532","BK4007","OZEM","LU1093756168.USD","NVOH","LU1093756325.SGD","BK4588","BK4599","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669386103","title":"Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and Alcon (ALC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669386103","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669386103?lang=en_us&edition=fundamental","pubTime":"2026-09-23 14:50","pubTimestamp":1790146217,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO) and Alcon (ALC). Novo Nordisk (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-novo-nordisk-nvo-and-alcon-alc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-novo-nordisk-nvo-and-alcon-alc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVOC","OZEM","NVO","BK4599","LU1804176565.USD","BK4007","IE00BZ1G4Q59.USD","ALC","LU2265009873.SGD","LU1093756325.SGD","BK4588","LU0154236417.USD","NVOX","THNR","BK4198","LU1093756168.USD","BK4532","BK4534","IE00BKVL7J92.USD","PPH","BK4585","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669126717","title":"Cboe data shows mixed options sentiment in Novo Nordisk with shares down 0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669126717","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669126717?lang=en_us&edition=fundamental","pubTime":"2026-09-23 01:15","pubTimestamp":1790097314,"startTime":"0","endTime":"0","summary":"Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares down 36c near $39.45. Options volume running well above average with 73k...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-novo-nordisk-with-shares-down-0-89-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-novo-nordisk-with-shares-down-0-89-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","NVOC","LU1093756325.SGD","BK4599","IE00BKVL7J92.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","NVO","NVOX","OZEM","PPH","THNR","BK4588","BK4532","NVOH","BK4007","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669140420","title":"European Pharma Leaders Push for National Reforms to Boost Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2669140420","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669140420?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:14","pubTimestamp":1790086440,"startTime":"0","endTime":"0","summary":"Several drugmakers urged European authorities to increase health budgets and speed up approvals for new medicines, warning the region is losing out to the U.S. and China in the race to attract investm","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","LU0889565916.HKD","BK4568","03165","LU2468319806.SGD","LU2236285917.USD","IE00BKVL7J92.USD","LU0029864427.USD","NVOH","PPH","GSK","NVOX","LU2456880835.USD","BK4578","IE00BZ1G4Q59.USD","LU2089984988.USD","HRTS","LU0070302665.USD","AZN","IE00BJJMRZ35.SGD","BK4599","GSKH","LU1829250122.USD","SNY","RHHBY","LU2237443978.SGD","BK4588","LU2237443382.USD","THNR","LU0320765992.SGD","LU2237443622.USD","BK4585","LU0432979614.USD","LU2237443549.SGD","IE0002141913.USD","NVO","LU0109394709.USD","LU0128525929.USD","NVOC","IE0009355771.USD","LU0708994859.HKD","LU2237443465.HKD","LU1093756325.SGD","LU0211331839.USD","IE00B4R5TH58.HKD","LU0208291251.USD","IE00B2B36J28.USD","LU0310800379.SGD","BK4007","BK4532","LU0058720904.USD","CANC","OZEM","LU0154236417.USD","LU0289739699.SGD","LU0320765489.SGD","LU1267930573.SGD","LU2237443895.HKD","IE00B3T34201.USD","IE00BFXG1179.USD","LU2462157665.USD","LU1093756168.USD","GSK.UK","NVS","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU2417539215.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142790","title":"Viking Therapeutics Stock Surges 35%. It Could Challenge Lilly and Novo's Obesity Empire","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142790","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142790?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:47","pubTimestamp":1790084874,"startTime":"0","endTime":"0","summary":"Eli Lilly and Novo Nordisk have been locked in a fierce battle to corner the weight-loss market, and while it is effectively a duopoly now, emerging competitors could soon challenge their...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Viking Therapeutics Stock Surges. It Could Challenge Lilly and Novo's Obesity Empire","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0943347566.SGD","LU1057294990.SGD","LU2089284900.SGD","SG9999018865.SGD","LU1988902786.USD","LU2168564065.EUR","LU0320765992.SGD","LU1064131342.USD","IE00BN29S564.USD","LU0210536198.USD","LU2111349929.HKD","LU2211815571.USD","LU2324357040.USD","LU1868836591.USD","HRTS","MEDI","IE00BK4W5M84.HKD","LU2456880835.USD","BK4599","LU0106261372.USD","LU1551013342.USD","IE00BJJMRX11.SGD","LU0889565916.HKD","LU0689472784.USD","CANC","LU1989771016.USD","GB00BDT5M118.USD","TMED","IE00BFSS7M15.SGD","LU2237443382.USD","LU2264538146.SGD","IE0004445239.USD","LLYZ","MEDX","IE0002141913.USD","LU0345770308.USD","LU0820562030.AUD","LU0238689110.USD","IE00B2B36J28.USD","LU2112291526.USD","WDNA","LU0354030438.USD","LU2746668974.SGD","LU1023059063.AUD","LU2471134879.HKD","LU0354030511.USD","LU1720051017.SGD","SG9999018857.SGD","LU0109391861.USD","LU2552382215.SGD","LU0203201768.USD","LU2750360641.GBP","FTXH","LU0708995401.HKD","BK4533","LU2360106947.USD","MHIP","LU0323591593.USD","LU0266013472.USD","SGXZ31699556.SGD","LU2213496289.HKD","BK4139","IE00BJLML261.HKD","LU0198837287.USD","LU0353189763.USD","LU0456855351.SGD","IE00BJJMRZ35.SGD","SG9999015945.SGD","SG9999015986.USD","LU2237443549.SGD","LU1814569148.SGD","LU2106854487.HKD","NVOH","LU1232071149.USD","LU2237443465.HKD","SGXZ51526630.SGD","LU2063271972.USD","LU2361044865.SGD","ELIS","BK4007","IE0001KFT4U8.USD","LU1280957306.USD","SG9999001176.USD","IE00B775H168.HKD","LU2471134523.USD","SG9999013999.USD","BK4585","SGXZ99366536.SGD","VHT","LU0820561909.HKD","LU1551013425.SGD","LU2602419157.SGD","LU1983299246.USD","LU0320765059.SGD","LU0820561818.USD","LU2023250330.USD","JDOC","LU1127390331.HKD","LU2168564222.USD","IE0009355771.USD","LU0203202063.USD","LU0234572021.USD","LU0640476718.USD","LU1366192091.USD","LU1868837300.USD","LU1868836757.USD","LU0353189680.USD","THNR","SG9999001176.SGD","XLV","IE00BWXC8680.SGD","LU1323610961.USD","LU1623119135.USD","LU1979441026.SGD","SG9999014880.SGD","IE00B4JS1V06.HKD","IE00B7KXQ091.USD","IE00BJJMRY28.SGD","IE00B4R5TH58.HKD","BK4588","IE00BFTCPJ56.SGD","LU0289739699.SGD","PPH","LU0154236417.USD","LU0225283273.USD","LU1093756325.SGD","FHLC","LU2087625088.SGD","LU2237443895.HKD","LU2462591350.SGD","LU2468319806.SGD","SG9999014914.USD","LU0174119429.USD","LU2417539215.USD","ILDR","LU1917777945.USD","LU2552382132.HKD","LU0385154629.USD","BK4534","NVO","LLYX","LU0079474960.USD","LU2357305700.SGD","LU1629891620.HKD","LU1691799644.USD","LU2265009873.SGD","LU2552382058.USD","LU2168564495.EUR","LU1035775433.USD","LU2756315318.SGD","LU0417517546.SGD","LLY","LU1712237335.SGD","BK4516","IE0005OL40V9.USD","LU0096364046.USD","LU0471298777.SGD","OZEM","LU0114720955.EUR","LU0006306889.USD","LU0256863811.USD","LU0094547139.USD","LU1720051108.HKD","LU0683600562.USD","LU2471134796.USD","LU0058720904.USD","LU0823416689.USD","LU0345770993.USD","LU2471134952.CNY","VKTX","IE00BFSS8Q28.SGD","LU0133085943.USD","IE00BZ1G4Q59.USD","AGNG","IE0004445015.USD","LU1267930730.SGD","IE00BK4W5L77.USD","LU0882574055.USD","LU2168564149.EUR","LU0256863902.USD","LU1061106388.HKD","GDOC","LU0316494557.USD","LU0823434583.USD","LU2089984988.USD","LU2361044949.HKD","LU2750360997.AUD","SG9999014898.SGD","IE00B1XK9C88.USD","LU1868837136.USD","LU0823434740.USD","LU0158827781.USD","LU2237438978.USD","NVOX","LU2271345857.HKD","LU1093756168.USD","SG9999015952.SGD","LU2023251221.USD","LU2089283258.USD","LU1145028129.USD","LU2491050154.USD","LU2236285917.USD","ELIL","LU0432979614.USD","IE00B1BXHZ80.USD","SG9999017495.SGD","LU0787776722.HKD","SGXZ81514606.USD","LU2461242641.AUD","LU2756315664.SGD","NVOC","LU1548497426.USD","LU0122379950.USD","SG9999015978.USD","LU0466842654.USD","LU1804176565.USD","LU0882574139.USD","LU2491050071.SGD","LU0786609619.USD","LU1974910355.USD","LU2896262040.SGD","SGXZ57979304.SGD","SG9999014906.USD","BK4581","IYH","CURE","LU2108987350.USD","LU1291159041.SGD","LU2168563687.JPY","RXL","LU2237443622.USD","TRUH","LU0672654240.SGD","LU2023250504.SGD","LU0158827948.USD","LU2028103732.USD","LU2237443978.SGD","LU0097036916.USD","LU2361045086.USD","LU2491049909.HKD","IE00BKPKM429.USD","IE00BKVL7J92.USD","LU1868836914.USD","LU2462157665.USD","IHE","LLII","IE00BJT1NW94.SGD","PJP","IXJ","LU0061475181.USD","BK4532","LU1069344957.HKD","IE00BKDWB100.SGD","LU2746668461.USD","LU0109394709.USD","LU0471298694.HKD","LU0964807845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142751","title":"Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142751","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142751?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:06","pubTimestamp":1790082402,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upSept 22 (Reuters)-The weight-loss drug market is booming, with biotech firms racing to capture a slice of the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","MEDI","IE00BKDWB100.SGD","IE00BJLML261.HKD","IE00BKVL7J92.USD","LU0672654240.SGD","HRTS","IE0004445239.USD","LU1551013425.SGD","LU2461242641.AUD","LU0882574139.USD","LU2462591350.SGD","LU2271345857.HKD","LU1979441026.SGD","LU2213496289.HKD","LU0203202063.USD","LU0061475181.USD","LU1720051108.HKD","LU0471298694.HKD","LU0820561818.USD","LU1323610961.USD","LU0320765059.SGD","AGNG","LU2491049909.HKD","LU2746668974.SGD","LU1366192091.USD","LU1061106388.HKD","LU1551013342.USD","NVO","LU0079474960.USD","LU2236285917.USD","LU0823434740.USD","LU2237443622.USD","LU0109394709.USD","BK4585","LU0097036916.USD","LU2471134879.HKD","MHIP","LU1291159041.SGD","LU1057294990.SGD","LU1989771016.USD","LU2361044949.HKD","LU0320765992.SGD","LU1064131342.USD","IE00BJJMRX11.SGD","BK4581","LU2417539215.USD","LU2237443895.HKD","SG9999015945.SGD","LU1983299246.USD","LU0466842654.USD","IE00BKPKM429.USD","LU2112291526.USD","LU1267930730.SGD","IYH","RXL","LU0122379950.USD","LU0354030511.USD","FTXH","LU2168564495.EUR","IXJ","LU1691799644.USD","LU2750360641.GBP","IE00B1BXHZ80.USD","SG9999015986.USD","LU2896262040.SGD","PJP","IE00B4R5TH58.HKD","IE00BJJMRY28.SGD","LU0158827781.USD","LU0689472784.USD","LU2264538146.SGD","LU0385154629.USD","LU1623119135.USD","SG9999014898.SGD","LU0823434583.USD","LU0106261372.USD","IE0002141913.USD","LU2237438978.USD","SG9999014906.USD","SGXZ99366536.SGD","LU0432979614.USD","LU2756315318.SGD","CURE","VHT","IE00B1XK9C88.USD","LU0256863902.USD","TRUH","IE0009355771.USD","LU0708995401.HKD","LU0354030438.USD","JDOC","LLYX","BK4007","LU2265009873.SGD","LU2357305700.SGD","THNR","PPH","LU1127390331.HKD","LU2168564222.USD","LU0266013472.USD","LU1868836914.USD","IE00BJJMRZ35.SGD","LU0109391861.USD","LU2361044865.SGD","BK4533","SG9999017495.SGD","BK4532","LU2552382132.HKD","SGXZ31699556.SGD","SG9999018857.SGD","LU2168564065.EUR","LU0345770308.USD","IE00B7KXQ091.USD","LU0225283273.USD","BK4599","LU2746668461.USD","LU1712237335.SGD","LU0114720955.EUR","LU0889565916.HKD","LU1868837300.USD","LU2089283258.USD","IE0004445015.USD","LU0943347566.SGD","LU1093756325.SGD","LU2168563687.JPY","LU2324357040.USD","LU0154236417.USD","IE00BFTCPJ56.SGD","LU0006306889.USD","LU2471134952.CNY","XLV","LU1035775433.USD","LU1988902786.USD","LU0417517546.SGD","LLY","SGXZ57979304.SGD","LU2756315664.SGD","MEDX","BK4516","IE00BK4W5M84.HKD","LU0787776722.HKD","LU1093756168.USD","LU0158827948.USD","LU2491050071.SGD","LU2168564149.EUR","IE00BK4W5L77.USD","LU2106854487.HKD","LU2602419157.SGD","LU2063271972.USD","LU2456880835.USD","CANC","LU2471134523.USD","LU2750360997.AUD","LU1023059063.AUD","LU2108987350.USD","LU2462157665.USD","LU2491050154.USD","SG9999015978.USD","LU0640476718.USD","LU0823416689.USD","LU0353189763.USD","LU0471298777.SGD","LU2471134796.USD","BK4534","LU2089984988.USD","LU1280957306.USD","LU0683600562.USD","NVOH","IE00BFSS7M15.SGD","LU0058720904.USD","LU1232071149.USD","LU0786609619.USD","LLYZ","LLII","LU2087625088.SGD","IE00BFSS8Q28.SGD","LU2111349929.HKD","LU2361045086.USD","NVOC","ELIS","LU0210536198.USD","IE00B4JS1V06.HKD","LU0323591593.USD","IE0001KFT4U8.USD","BK4588","TMED","LU2237443978.SGD","LU1069344957.HKD","LU0238689110.USD","LU1868836591.USD","LU0133085943.USD","SGXZ81514606.USD","LU2468319806.SGD","WDNA","LU2023250504.SGD","SG9999013999.USD","LU0174119429.USD","LU0094547139.USD","GB00BDT5M118.USD","LU0203201768.USD","LU0316494557.USD","OZEM","NVOX","LU2552382215.SGD","LU1720051017.SGD","LU1548497426.USD","IE00BWXC8680.SGD","LU0456855351.SGD","SG9999014914.USD","LU2211815571.USD","IE00BJT1NW94.SGD","ILDR","LU1145028129.USD","IHE","IE00BZ1G4Q59.USD","LU1814569148.SGD","LU0198837287.USD","LU0820562030.AUD","LU2089284900.SGD","FHLC","LU2237443465.HKD","LU2360106947.USD","SG9999001176.SGD","SGXZ51526630.SGD","LU1804176565.USD","IE0005OL40V9.USD","LU1629891620.HKD","LU2023250330.USD","LU0820561909.HKD","GDOC","LU2237443549.SGD","LU1868836757.USD","LU1917777945.USD","SG9999001176.USD","LU2028103732.USD","SG9999014880.SGD","LU1974910355.USD","LU0964807845.USD","SG9999018865.SGD","LU0234572021.USD","SG9999015952.SGD","IE00B2B36J28.USD","IE00B775H168.HKD","LU1868837136.USD","IE00BN29S564.USD","LU0353189680.USD","LU2552382058.USD","LU2237443382.USD","LU0345770993.USD","LU0256863811.USD","LU0289739699.SGD","LU2023251221.USD","ELIL","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.2118},{"period":"1month","weight":-0.3897},{"period":"3month","weight":-0.3931},{"period":"6month","weight":0.055},{"period":"1year","weight":-0.6933},{"period":"ytd","weight":-0.5528}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.2099},{"period":"1year","weight":0.1605},{"period":"ytd","weight":0.125}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"ARCA","name":"Defiance Daily Target 2X Long NVO ETF","nameEN":"Defiance Daily Target 2X Long NVO ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Defiance Daily Target 2X Long NVO ETF(NVOX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Defiance Daily Target 2X Long NVO ETF(NVOX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Defiance Daily Target 2X Long NVO ETF,NVOX,Defiance Daily Target 2X Long NVO ETF股票,Defiance Daily Target 2X Long NVO ETF股票老虎,Defiance Daily Target 2X Long NVO ETF股票老虎国际,Defiance Daily Target 2X Long NVO ETF行情,Defiance Daily Target 2X Long NVO ETF股票行情,Defiance Daily Target 2X Long NVO ETF股价,Defiance Daily Target 2X Long NVO ETF股市,Defiance Daily Target 2X Long NVO ETF股票价格,Defiance Daily Target 2X Long NVO ETF股票交易,Defiance Daily Target 2X Long NVO ETF股票购买,Defiance Daily Target 2X Long NVO ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Defiance Daily Target 2X Long NVO ETF(NVOX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Defiance Daily Target 2X Long NVO ETF(NVOX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction